IVVD Invivyd, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 13, 2026
$0,82
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$0,5352-Wochen-Tief
$3,0752-Wochen-Hoch
Marktkapitalisierung (MRQ)
$242M
P/E (TTM)
-2.7
EPS (TTM)
$-0.31
Umsatz (TTM)
$58M
Ihre Abzeichen
52W-Spanne
$1–$3
Analystenbewertung
BUY
Kursziel
$10
P/E
-2.7
ROE
-95.9%
Nettogewinnmarge
-183.9%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
IVVD Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$0.82
Marktkapitalisierung (MRQ)
$242M
P/E (TTM)
-2.7
EPS (TTM)
$-0.31
Umsatz (TTM)
$58M
ROE (TTM)
-95.9%
52W-Spanne
$1–$3
IVVD Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$53M2023-12-31 → 2025-12-31
EPS$-0.302021-12-31 → 2025-12-31
Freier Cashflow$-58M2022-12-31 → 2025-12-31
Nettogewinnmarge-183.9%2024-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | IVVD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -2.75-Jahres-Durchschnitt ≈-2.6 | ≈-2.6 | · | · | |
| P/S (TTM) | 4.2 | · | 44.0 | Unterbewertet | |
| K/B (MRQ) | 1.35-Jahres-Durchschnitt ≈1.6 | ≈1.6 | 2.1 | Unterbewertet | |
| Kurs / FCF (TTM) | -2.25-Jahres-Durchschnitt ≈-3.9 | ≈-3.9 | · | · | |
| Kurs / Cashflow (TTM) | -2.25-Jahres-Durchschnitt ≈-3.9 | ≈-3.9 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 1.05-Jahres-Durchschnitt ≈1.6 | ≈1.6 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | IVVD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -192.8% | · | -320.8% | Im Einklang | |
| EBITDA Margin (EBITDA-Marge) | -104.0% | · | -320.8% | Im Einklang | |
| Nettogewinnmarge (TTM) | -183.9% | · | -692.5% | Spitzenklasse | |
| ROA (TTM) | -69.7%5-Jahres-Durchschnitt ≈-58.4% | ≈-58.4% | -29.4% | Spitzenklasse | |
| ROE (TTM) | -95.9%5-Jahres-Durchschnitt ≈-105.5% | ≈-105.5% | -47.7% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | IVVD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 5.95-Jahres-Durchschnitt ≈7.1 | ≈7.1 | 7.5 | Geringe Liquidität | |
| Quick Ratio | 7.05-Jahres-Durchschnitt ≈4.0 | ≈4.0 | 5.5 | Im Einklang |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | IVVD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 110.5% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | IVVD | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.3 | · | 0.1 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 4.3 | · | · | · | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$437.9K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-130.4%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 13, 2026 | $-0.14 | $-0.11 | -28.7% |
| 31. März 2026 | Mai 14, 2026 | $-0.13 | $-0.07 | -73.8% |
| 31. Dezember 2025 | $-0.04 | $-0.09 | 55.2% | |
| 30. September 2025 | $-0.06 | $-0.08 | 26.5% | |
| 30. Juni 2025 | $-0.12 | $-0.02 | -404.2% | |
| 31. März 2025 | $-0.14 | $-0.03 | -357.5% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $53M | $25M | $0 | |
| R&D Expense | $38M | $137M | $159M | |
| SG&A Expense | $67M | $63M | $49M | |
| Operating Expenses | $109M | $202M | $213M | |
| Operating Income | $-56M | $-177M | $-213M | |
| Other Non-op | $3M | $7M | $14M | |
| Income Tax | $0 | $0 | $0 | |
| Net Income | $-52M | $-170M | $-199M | |
| EPS (Basic) | $-0.30 | $-1.43 | $-1.81 | |
| EPS (Diluted) | $-0.30 | $-1.43 | $-1.81 | |
| Shares (Basic) | 172,212,902 | 118,555,073 | 109,526,053 | |
| Shares (Diluted) | 172,212,902 | 118,555,073 | 109,526,053 | |
| EBITDA | $-56M | $-177M | $-213M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $227M | $69M | $201M | |
| Receivables | $14M | $11M | $0 | |
| Inventory | · | $26M | $0 | |
| Prepaid Expense | $7M | $20M | $24M | |
| Other Current Assets | · | $4M | · | |
| Current Assets | $247M | $101M | $225M | |
| PP&E (Net) | $1M | $2M | $2M | |
| Other Non-current Assets | $110.0K | $34.0K | $175.0K | |
| Total Assets | $277M | $130M | $229M | |
| Accounts Payable | $14M | $10M | $8M | |
| Accrued Liabilities | $19M | $50M | $41M | |
| Current Liabilities | $34M | $62M | $50M | |
| Capital Leases | $1M | $0 | $722.0K | |
| Other Non-current Liabilities | · | $0 | $700.0K | |
| Total Liabilities | $35M | $62M | $52M | |
| Common Stock | $28.0K | $12.0K | $11.0K | |
| Retained Earnings | $-954M | $-902M | $-732M | |
| AOCI | $-41.0K | $-5.0K | $-13.0K | |
| Stockholders' Equity | $242M | $68M | $177M | |
| Liabilities + Equity | $277M | $130M | $229M | |
| Shares Outstanding | 281,987,033 | 119,835,162 | 110,160,684 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $12M | $20M | $19M | |
| Operating Cash Flow | $-58M | $-170M | $-173M | |
| CapEx | $155.0K | $140.0K | $615.0K | |
| Investing Cash Flow | $-155.0K | $-140.0K | $281M | |
| Stock Issued | $254.0K | $223.0K | $240.0K | |
| Stock Repurchased | · | $0 | $1.0K | |
| Net Stock Activity | $254.0K | $223.0K | $239.0K | |
| Financing Cash Flow | $216M | $39M | $1M | |
| Net Change in Cash | $157M | $-131M | $109M | |
| Free Cash Flow | $-58M | $-171M | $-174M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Operating Margin | -104.0% | -696.8% | · | |
| Net Margin | -98.2% | -669.4% | · | |
| EBITDA Margin | -104.0% | -696.8% | · | |
| ROA | -25.8% | -94.8% | -64.9% | |
| ROE | -36.9% | -225.5% | -93.7% |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Current Ratio | 7.2 | 1.6 | 4.5 | |
| Quick Ratio | 7.0 | 1.3 | 4.0 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.1 | · | |
| Receivables Turnover | 4.3 | 4.7 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Book Value / Share | $0.86 | $0.56 | $1.61 | |
| Revenue / Share | $0.31 | $0.21 | · | |
| Cash Flow / Share | $-0.34 | $-1.44 | $-1.58 | |
| Cash / Share | $0.80 | $0.58 | $1.82 | |
| EPS (TTM) | $-0.30 | $-1.43 | $-1.81 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue YoY | 110.5% | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue TTM | $53M | $25M | $0 | |
| Net Income TTM | $-52M | $-170M | $-199M | |
| Market Cap | $697M | $53M | $434M | |
| P/E | -8.2 | -0.3 | -2.2 | |
| P/S | 13.0 | 2.1 | · | |
| P/B | 2.9 | 0.8 | 2.4 | |
| P / Tangible Book | 2.9 | 0.8 | 2.4 | |
| P / Cash Flow | -12.0 | -0.3 | -2.5 | |
| P / FCF | -11.9 | -0.3 | -2.5 | |
| Earnings Yield | -12.2% | -322.8% | -45.9% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $14M | $17M | $13M | $12M | $11M | $14M | $9M | $2M | $0 | $0 | $0 | $0 | |
| R&D Expense | $29M | $31M | $10M | $8M | $10M | $11M | $18M | $58M | $30M | $31M | $62M | $26M | $44M | |
| SG&A Expense | $29M | $25M | $19M | $15M | $17M | $17M | $14M | $13M | $21M | $15M | $15M | $13M | $10M | |
| Operating Expenses | $60M | $57M | $30M | $24M | $27M | $28M | $33M | $72M | $52M | $46M | $77M | $43M | $54M | |
| Operating Income | $-46M | $-43M | $-13M | $-11M | $-15M | $-17M | $-19M | $-62M | $-49M | $-46M | $-77M | $-43M | $-54M | |
| Other Non-op | $1M | $2M | $1M | $553.0K | $400.0K | $633.0K | $786.0K | $2M | $2M | $3M | $3M | $4M | $4M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-44M | $-41M | $-11M | $-10M | $-15M | $-16M | $-18M | $-61M | $-47M | $-43M | $-74M | $-39M | $-50M | |
| EPS (Basic) | $-0.14 | $-0.13 | $0.02 | $-0.06 | $-0.12 | $-0.14 | $-0.14 | $-0.51 | $-0.40 | $-0.38 | $-0.67 | $-0.36 | $-0.46 | |
| EPS (Diluted) | $-0.14 | $-0.13 | $0.02 | $-0.06 | $-0.12 | $-0.14 | $-0.14 | $-0.51 | $-0.40 | $-0.38 | $-0.67 | $-0.36 | $-0.46 | |
| Shares (Basic) | 320,435,078 | 309,670,101 | · | 170,169,865 | 120,016,132 | 119,883,479 | · | 119,495,284 | 119,362,670 | 115,618,209 | · | 109,754,812 | 109,450,071 | |
| Shares (Diluted) | 320,435,078 | 309,670,101 | · | 170,169,865 | 120,016,132 | 119,883,479 | · | 119,495,284 | 119,362,670 | 115,618,209 | · | 109,754,812 | 109,450,071 | |
| EBITDA | $-46M | $-43M | · | $-11M | $-15M | $-17M | · | $-62M | $-49M | $-46M | · | $-43M | $-54M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $160M | $184M | $227M | $85M | $35M | $48M | $69M | $107M | $148M | $189M | $201M | $182M | $122M | |
| Receivables | $11M | $12M | $14M | $10M | $9M | $9M | $11M | $8M | $3M | · | $0 | · | · | |
| Inventory | · | · | · | $25M | $25M | $25M | · | $27M | $5M | $109.0K | $0 | · | · | |
| Prepaid Expense | $11M | $9M | $7M | $15M | $16M | $19M | $20M | $9M | $17M | $20M | $24M | $5M | $12M | |
| Other Current Assets | · | · | · | · | $2M | · | · | · | · | · | · | · | · | |
| Current Assets | $182M | $205M | $247M | $110M | $59M | $76M | $101M | $151M | $173M | $210M | $225M | $270M | $310M | |
| PP&E (Net) | $2M | $2M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Other Non-current Assets | $1M | $1M | $110.0K | $6.0K | $15.0K | $24.0K | $34.0K | $7M | $2M | $2M | $175.0K | $187.0K | $291.0K | |
| Total Assets | $219M | $242M | $277M | $139M | $89M | $104M | $130M | $162M | $177M | $215M | $229M | $275M | $315M | |
| Accounts Payable | $9M | $2M | $14M | $18M | $18M | $9M | $10M | $18M | $7M | $1M | $8M | $9M | $4M | |
| Accrued Liabilities | $20M | $28M | $19M | $25M | $25M | $40M | $50M | $59M | $27M | $34M | $41M | $16M | $27M | |
| Current Liabilities | $31M | $32M | $34M | $44M | $44M | $50M | $62M | $79M | $37M | $36M | $50M | $27M | $33M | |
| Capital Leases | $7M | $7M | $1M | $2M | $2M | $0 | $0 | $219.0K | $0 | $625.0K | $722.0K | $927.0K | $1M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $0 | $0 | $0 | $700.0K | $700.0K | · | |
| Total Liabilities | $38M | $39M | $35M | $46M | $46M | $50M | $62M | $79M | $37M | $37M | $52M | $28M | $34M | |
| Common Stock | $29.0K | $28.0K | $28.0K | $22.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $11.0K | $11.0K | $11.0K | |
| Retained Earnings | $-1.04B | $-996M | $-954M | $-943M | $-933M | $-918M | $-902M | $-884M | $-823M | $-776M | $-732M | $-658M | $-619M | |
| AOCI | $-35.0K | $-37.0K | $-41.0K | $-41.0K | $-39.0K | $-13.0K | $-5.0K | $-18.0K | $-12.0K | $-12.0K | $-13.0K | $-2.0K | $-22.0K | |
| Stockholders' Equity | $181M | $203M | $242M | $93M | $43M | $54M | $68M | $83M | $141M | $178M | $177M | $246M | $282M | |
| Liabilities + Equity | $219M | $242M | $277M | $139M | $89M | $104M | $130M | $162M | $177M | $215M | $229M | $275M | $315M | |
| Shares Outstanding | 294,755,090 | 282,803,863 | 281,987,033 | 214,409,450 | 120,142,811 | 119,961,445 | 119,835,162 | 119,604,035 | 119,442,635 | 119,221,230 | 110,160,684 | 109,846,329 | 109,570,333 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $8M | $5M | $4M | $4M | $5M | |
| Operating Cash Flow | $-43M | $-42M | $-15M | $-8M | $-13M | $-21M | $-38M | $-41M | $-42M | $-50M | $-59M | $-35M | $-37M | |
| CapEx | $510.0K | $726.0K | $0 | $0 | $11.0K | $144.0K | $-5.0K | $5.0K | $0 | $140.0K | $0 | $0 | $-9.0K | |
| Investing Cash Flow | $-510.0K | $-726.0K | $0 | $0 | $-11.0K | $-144.0K | $5.0K | $-5.0K | $0 | $-140.0K | $78M | $95M | $33M | |
| Stock Issued | $120.0K | $135.0K | $76.0K | $56.0K | $78.0K | $44.0K | $32.0K | $27.0K | $75.0K | $89.0K | $44.0K | $57.0K | $56.0K | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | · | · | $0 | $0 | $1.0K | |
| Net Stock Activity | · | $135.0K | · | · | · | $44.0K | · | · | · | $89.0K | · | · | · | |
| Financing Cash Flow | $19M | $-98.0K | $157M | $58M | $131.0K | $10.0K | $77.0K | $61.0K | $92.0K | $39M | $141.0K | $92.0K | $270.0K | |
| Net Change in Cash | $-24M | $-43M | $142M | $50M | $-13M | $-21M | $-38M | $-41M | $-42M | $-11M | $19M | $60M | $-5M | |
| Free Cash Flow | · | $-42M | · | · | · | $-21M | · | · | · | $-50M | · | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -320.8% | -313.9% | · | -84.0% | -127.8% | -149.7% | · | -670.0% | -2175.2% | · | · | · | · | |
| Net Margin | -310.8% | -301.2% | · | -79.8% | -124.4% | -144.1% | · | -653.1% | -2086.9% | · | · | · | · | |
| EBITDA Margin | -320.8% | -313.9% | · | -84.0% | -127.8% | -149.7% | · | -670.0% | -2175.2% | · | · | · | · | |
| ROA | -28.8% | -24.0% | · | -7.0% | -11.0% | -10.2% | · | -27.8% | -19.2% | -15.4% | · | -11.3% | -12.6% | |
| ROE | -39.7% | -32.2% | · | -11.9% | -16.0% | -14.0% | · | -36.9% | -22.4% | -17.2% | · | -12.6% | -14.4% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.9 | 6.5 | · | 2.5 | 1.3 | 1.5 | · | 1.9 | 4.7 | 5.8 | · | 10.1 | 9.5 | |
| Quick Ratio | 5.5 | 6.2 | · | 2.1 | 1.0 | 1.1 | · | 1.5 | 4.1 | 5.2 | · | 6.8 | 3.8 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.0 | 0.0 | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.5 | 2.0 | 2.6 | · | 2.3 | 1.6 | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.61 | $0.72 | · | $0.43 | $0.36 | $0.45 | · | $0.70 | $1.18 | $1.50 | · | $2.24 | $2.57 | |
| Revenue / Share | $0.04 | $0.04 | · | $0.08 | $0.10 | $0.09 | · | $0.08 | $0.02 | · | · | · | · | |
| Cash Flow / Share | · | $-0.13 | · | · | · | $-0.18 | · | · | · | $-0.43 | · | · | · | |
| Cash / Share | $0.54 | $0.65 | · | $0.40 | $0.29 | $0.40 | · | $0.89 | $1.24 | $1.59 | · | $1.66 | $1.11 | |
| EPS (TTM) | $-0.31 | $-0.29 | · | $-0.46 | $-0.91 | $-1.19 | · | $-1.96 | $-1.81 | $-1.87 | · | $-1.55 | $-1.61 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $58M | $56M | · | $50M | $46M | $37M | · | $12M | $2M | $0 | · | · | · | |
| Net Income TTM | $-107M | $-78M | · | $-60M | $-110M | $-143M | · | $-225M | $-204M | $-207M | · | $-170M | $-175M | |
| Market Cap | $257M | $368M | · | $236M | $86M | $73M | · | $122M | $131M | $529M | · | $187M | $115M | |
| P/E | -2.8 | -4.5 | · | -2.4 | -0.8 | -0.5 | · | -0.5 | -0.6 | -2.4 | · | -1.1 | -0.7 | |
| P/S | 4.4 | 6.6 | · | 4.7 | 1.9 | 2.0 | · | 10.5 | 58.0 | · | · | · | · | |
| P/B | 1.4 | 1.8 | · | 2.5 | 2.0 | 1.3 | · | 1.5 | 0.9 | 3.0 | · | 0.8 | 0.4 | |
| P / Tangible Book | 1.4 | 1.8 | · | 2.5 | 2.0 | 1.3 | · | 1.5 | 0.9 | 3.0 | · | 0.8 | 0.4 | |
| P / Cash Flow | · | -8.8 | · | · | · | -3.4 | · | · | · | -10.5 | · | · | · | |
| Earnings Yield | -35.5% | -22.3% | · | -41.8% | -127.3% | -196.7% | · | -192.2% | -164.5% | -42.1% | · | -91.2% | -153.3% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $53M | $25M | $0 | · | · |
| Betriebsgewinnmarge % | -104.0% | -696.8% | · | · | · |
| Nettoergebnis | $-52M | $-170M | $-199M | $-241M | $-227M |
| Verwässerte EPS | $-0.30 | $-1.43 | $-1.81 | $-2.23 | $-5.32 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 7.2 | 1.6 | 4.5 | 15.1 | · |
| Quick Ratio | 7.0 | 1.3 | 4.0 | 3.7 | · |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-58M | $-171M | $-174M | $-222M | · |
Institutionelle Eigentümer (13F) 139 Einreicher · $257.2M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
139
Gehaltener Wert
$257.2M
Neue Positionen
34
Geschlossene Positionen
43
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 34 (-9 vs. Vorquartal) | 43 (+29 vs. Vorquartal) | 41 (+3 vs. Vorquartal) | 28 (-2 vs. Vorquartal) | -26.3M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | $42.857.157 | 33.094.330 | 16,66% | Aktien |
| VANGUARD GROUP INC | $26.438.823 | 10.703.977 | 10,28% | Aktien |
| BVF INC/IL | $24.571.146 | 28.165.000 | 9,55% | Aktien |
| MAVERICK CAPITAL LTD | $16.550.225 | 18.970.913 | 6,44% | Aktien |
| PERCEPTIVE ADVISORS LLC | $16.131.231 | 18.490.636 | 6,27% | Aktien |
| BlackRock, Inc. | $14.076.073 | 16.134.885 | 5,47% | Aktien |
| Mithril II GP LP | $12.365.738 | 11.241.580 | 4,81% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.152.954 | 10.496.507 | 3,56% | Aktien |
| M28 Capital Management LP | $8.068.173 | 9.248.250 | 3,14% | Aktien |
| Saturn V Capital Management LP | $7.321.432 | 8.392.288 | 2,85% | Aktien |
| Soleus Capital Management, L.P. | $6.725.093 | 7.708.727 | 2,61% | Aktien |
| Point72 Asset Management, L.P. | $6.579.694 | 7.542.061 | 2,56% | Aktien |
| MORGAN STANLEY | $4.999.678 | 5.730.948 | 1,94% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $4.728.560 | 5.418.774 | 1,84% | Aktien |
| Siren, L.L.C. | $4.362.000 | 5.000.000 | 1,70% | Aktien |
| Driehaus Capital Management LLC | $4.193.228 | 4.806.543 | 1,63% | Aktien |
| ADAR1 Capital Management, LLC | $3.321.599 | 3.807.427 | 1,29% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $3.194.275 | 3.661.480 | 1,24% | Aktien |
| CITADEL ADVISORS LLC | $3.124.013 | 3.580.941 | 1,21% | Aktien |
| STATE STREET CORP | $3.016.260 | 3.457.428 | 1,17% | Aktien |
| Qube Research & Technologies Ltd | $2.896.576 | 3.320.238 | 1,13% | Aktien |
| Ikarian Capital, LLC | $2.317.592 | 2.656.570 | 0,90% | Aktien |
| Redmile Group, LLC | $2.266.285 | 2.597.759 | 0,88% | Aktien |
| TWO SIGMA ADVISERS, LP | $2.264.002 | 916.600 | 0,88% | Aktien |
| 683 Capital Management, LLC | $2.165.770 | 2.482.543 | 0,84% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $2.035.723 | 2.333.474 | 0,79% | Aktien |
| Eversept Partners, LP | $1.951.572 | 2.237.015 | 0,76% | Aktien |
| Ensign Peak Advisors, Inc | $1.501.641 | 1.721.276 | 0,58% | Aktien |
| NORTHERN TRUST CORP | $1.404.872 | 1.610.353 | 0,55% | Aktien |
| Boxer Capital Management, LLC | $1.308.600 | 1.500.000 | 0,51% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $1.272.258 | 1.459.012 | 0,49% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.236.262 | 1.417.732 | 0,48% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $1.051.765 | 1.205.599 | 0,41% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $868.329 | 995.334 | 0,34% | Aktien |
| GOLDMAN SACHS GROUP INC | $853.689 | 978.552 | 0,33% | Aktien |
| DEUTSCHE BANK AG\ | $687.952 | 790.749 | 0,27% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $675.792 | 774.635 | 0,26% | Aktien |
| UBS Group AG | $481.570 | 552.260 | 0,19% | Aktien |
| Bank of New York Mellon Corp | $451.833 | 517.920 | 0,18% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $409.781 | 469.717 | 0,16% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $397.412 | 455.539 | 0,15% | Aktien |
| Invesco Ltd. | $396.532 | 454.530 | 0,15% | Aktien |
| CANTOR FITZGERALD, L. P. | $392.680 | 450.115 | 0,15% | Aktien |
| EMERALD MUTUAL FUND ADVISERS TRUST | $374.126 | 428.847 | 0,15% | Aktien |
| Virtus Investment Advisers, LLC | $370.712 | 424.933 | 0,14% | Aktien |
| BANK OF AMERICA CORP /DE/ | $311.234 | 356.920 | 0,12% | Aktien |
| Birchview Capital, LP | $298.601 | 342.275 | 0,12% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $281.097 | 323.100 | 0,11% | Verkaufsoption |
| Nuveen, LLC | $244.563 | 280.333 | 0,10% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $241.599 | 277.700 | 0,09% | Kaufoption |
Aktivisten & 5%+-Eigentümer 5 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Adimab, LLC ×6 Einreichungen | 29. Dezember 2025 | 7,30% | Änderung | · | SEC |
| Mithril II LP, Mithril II GP LP, Mithril II UGP LLC, Ajay Royan, Peter Thiel ×6 Einreichungen | 12. November 2025 | 4,80% | Änderung | · | SEC |
| Polaris Venture Partners V, L.P., Polaris Venture Partners Entrepreneurs' Fund V, L.P., Polaris Venture Partners Founders' Fund V, L.P., Polaris Venture Partners Special Founders' Fund V, L.P., Polaris Venture Management Co. V, L.L.C., Polaris Partners IX, L.P., Polaris Partners GP IX, L.L.C., Polaris Healthcare Technology Opportunities Fund, L.P., Polaris Healthcare Technology Opportunities Fund GP, L.L.C., Terrance McGuire, Jonathan Flint ×6 Einreichungen | 7. November 2025 | 3,00% | Änderung | · | SEC |
| M28 Capital Management LP, Marc Elia ×5 Einreichungen | 26. August 2025 | 4,60% | Änderung | · | SEC |
| Population Health Equity Partners III, L.P., Population Health Equity Partners III GP, LLC, Population Health Equity Partners VII, L.P., Population Health Equity Partners VII GP, LLC, Clive Meanwell, Christopher Cox ×3 Einreichungen | 24. Juni 2022 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 33 Insider · 15 Führungskräfte · 19 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Marc Elia | Chief Executive Officer | 30. August 2026 A | · | 0 | 0 | $0 |
| David Hering | Chief Executive Officer | 18. Dezember 2023 A | 8.000 | 0 | 0 | $0 |
| Tillman U. Gerngross | Chief Executive Officer | 30. Januar 2022 A | 27.845.995 | 0 | 0 | $0 |
| William E. Duke | Chief Financial Officer | 15. August 2026 M | 168.937 | 0 | 4 | $-94.977 |
| Jane Henderson | Chief Financial Officer | 30. Januar 2022 A | · | 0 | 0 | $0 |
| Jeremy Gowler | COO & CCO | 18. Dezember 2023 A | · | 0 | 0 | $0 |
| Timothy Edward Lee | Chief Commercial Officer | 15. August 2026 M | 178.937 | 0 | 4 | $-94.977 |
| Julie Green | Chief Human Resources Officer | 15. August 2026 M | 168.937 | 0 | 4 | $-94.977 |
| Robert D. Allen III | Chief Scientific Officer | 15. August 2026 M | 178.765 | 0 | 4 | $-87.855 |
| Jill Andersen | Chief Legal Officer, Secretary | 15. August 2026 M | 283.774 | 0 | 4 | $-158.288 |
| Stacy Price | Chief Tech. and Manuf. Officer | 18. Dezember 2023 A | · | 0 | 0 | $0 |
| Peter Schmidt | Chief Medical Officer | 18. Dezember 2023 A | · | 0 | 0 | $0 |
| Rebecca Dabora | Chief Tech and Manuf Officer | 14. Dezember 2022 A | · | 0 | 0 | $0 |
| Lynn Connolly | Chief Medical Officer | 30. Januar 2022 A | · | 0 | 0 | $0 |
| Elham Hershberger | Chief Development Officer | 30. Januar 2022 A | · | 0 | 0 | $0 |
| Ian Sheffield | Direktor | 31. August 2026 A | · | 0 | 0 | $0 |
| Tamsin Berry | Direktor | 19. Mai 2026 A | · | 0 | 0 | $0 |
| Ajay Royan | Direktor | 19. Mai 2026 A | 11.241.580 | 0 | 0 | $0 |
| Paul Bolno | Direktor | 19. Mai 2026 A | · | 0 | 0 | $0 |
| Kevin F Mclaughlin | Direktor | 19. Mai 2026 A | 50.000 | 1 | 0 | $125.000 |
| Terrance McGuire | Direktor | 19. Mai 2026 A | 3.066.757 | 0 | 0 | $0 |
| Christine Lindenboom | Direktor | 20. Mai 2025 A | · | 0 | 0 | $0 |
| Srishti Gupta | Direktor | 21. Mai 2024 A | · | 0 | 0 | $0 |
| Sara Cotter | Direktor | 21. Mai 2024 A | · | 0 | 0 | $0 |
| Tomas J. Heyman | Direktor | 23. Mai 2023 A | · | 0 | 0 | $0 |
| Clive Meanwell | Direktor | 23. Mai 2023 A | · | 0 | 0 | $0 |
| Michael S Wyzga | Direktor | 23. Mai 2023 A | · | 0 | 0 | $0 |
| Redonda Miller | Direktor | 22. Juni 2022 A | · | 0 | 0 | $0 |
| Howard Mayer | Direktor | 22. Juni 2022 A | · | 0 | 0 | $0 |
| Ellen R Marram | Direktor | 19. November 2021 A | · | 0 | 0 | $0 |
| Rene Russo | Direktor | 5. August 2021 A | · | 0 | 0 | $0 |
| Adimab, LLC | 10%-Eigentümer | 19. Januar 2024 S | 21.687.906 | 0 | 0 | $0 |
| Michael Mina | · | 31. Juli 2026 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 13 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,47% | 403.655 NS | 31. Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,04% | 719.785 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,02% | 20.848 SH | 2. Oktober 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 405.677 SH | 2. Oktober 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 1.216.850 SH | 19. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 182.982 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,01% | 5.586.643 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,00% | 100.540 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 589.919 SH | 11. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 2.434.423 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 7.785.522 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 17.900 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 2.013.518 SH | 11. September 2026 | Täglich |
IVVD Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 9 Analysten
KAUF
Median-Ziel
$10.00
+1116,4%
3 33,3%
Starker Kauf
5 55,6%
Kauf
1 11,1%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
3 Analysten · 2026-10-04Mittelwert-Ziel $10.00 +1116,4%
Tief$10.00
Mittelwert$10.00
Hoch$10.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| IVVD | $697M | -8.2 | 110.5% | -98.2% | -36.9% | · |
| GLSI | $300M | -14.7 | · | · | -2159.7% | · |
| QTTB | $43M | 1.4 | · | 55.5% | 200.3% | · |
| CAMP | $318M | -2.3 | 436.5% | -2298.5% | -183.4% | · |
| EVMN | $540M | -1.5 | 85.7% | -529.8% | -401.2% | · |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | · |
| LYEL | $654M | -1.9 | -41.0% | -762355.6% | -100.3% | · |
| MGNX | $102M | -1.4 | -0.31% | -49.9% | -87.0% | · |
| KROS | $398M | 8.9 | · | 35.7% | 17.2% | · |
| RNAC | $188M | -1.4 | -92.8% | -4658.6% | 202.4% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 13, 2026